DV
Dividend Vision

THNR — Amplify Weight Loss Drug & Treatment ETF

Amplify Weight Loss Drug & Treatment ETF (THNR)

THNR pays a 1.63% distribution rate, on a 0.59% expense ratio. Its Distribution Safety Score™ is 50 (Caution). Total return is 5.7% over the past 2.2 years, 44.3 points behind SPY at 50.0%. Its deepest 1-year drawdown was 12.1%.

Amplify Weight Loss Drug & Treatment ETF is an ETF that tracks an index of global companies positioned to benefit from weight loss drug development, including pharmaceutical manufacturers, combination therapy makers, and telehealth providers offering GLP-1 and related medications. The fund carries a modest expense ratio of 0.59% and maintains a modest current distribution rate. It does not have a regular distribution frequency, making it primarily suited for investors seeking equity exposure to the weight loss treatment sector rather than current income.

THNR key facts

Distribution Safety Score™
50 · Caution
Issuer
Amplify ETFs
Asset type
ETF
Asset class
Equity
Inception date
05/20/2024
Expense ratio
0.59%
Distribution rate
1.63%
Trailing yield
1.58%
Last close
$26.16
AUM
$5,222,609
Average volume
1248.0
Last dividend
$0.4130
Ex-dividend date
12/30/2025
Payment date
12/31/2025
Beta
0.6942
P/E ratio
19.151